摘要
目的 评价氟哌噻吨美利曲辛对带状疱疹后遗神经痛常规治疗的优化效果.方法胸腰段PHN患者70例,性别不限,按就诊顺序编号分为2组(n=35):奇数号患者纳入对照组(C组),偶数号患者纳入氟哌噻吨美利曲辛组(D组). C组采用常规疗法:抗癫痫、阿片类药物镇痛、神经营养、椎旁神经阻滞和物理治疗. D组常规疗法基础上每天口服氟哌噻吨美利曲辛10.5 mg.记录治疗时间.于治疗前和治疗第3、7天采用数字量表评分(NRS评分)评估疼痛程度,采用医院焦虑抑郁量表(HADS)评估焦虑和抑郁情况.记录D组治疗期间氟哌噻吨美利曲辛相关不良反应的发生情况.结果 与C组比较,D组治疗第3、7天NRS评分和 HADS评分降低,治疗时间缩短( P<0. 05). D组均未见氟哌噻吨美利曲辛相关不良反应发生.结论 氟哌噻吨美利曲辛可优化带状疱疹后遗神经痛的常规疗效.
Objective To evaluate the efficacy of flupentixol and melitracen in optimizing conven- tional treatment for postherpetic neuralgia.Methods Seventy patients of both sexes with thoraeolumbar postherpetic netiralgia,were divided into 2groups (n =35each)according-to the registration order:pa- tients with odd number were included in control group (group C)and patients with even number were in- eluded in flupentixol-melitraeen group (group D).Patients in group C received conventional treatment:anti-epileptic drugs,analgesia with opioids,neurotrophy,paravertebral nerve block and physical therapy. Flupentixol-melitracen 10.5mg was taken orally based on the conventional treatment in group D.The time for treatment was recorded.The severity of pain was assessed by using the numeric rating scale,and anxiety and depression were evaluated using the Hospital Anxiety and Depression Scale before treatment and on 3rd and 7th days after treatment.The development of flupenthixol and melitracen-related adverse reactions was recorded during treatment in group D.Results Compared with group C,the numeric rating scale and Hos- pital Anxiety and Depression Scale scores were significantly decreased on 3rd and 7th days after treatment, and the time for treatment was shortened in group D (P<0.05).No flupenthixol-and melitraeen-related ad- verse reactions were found in group D.Conclusion Flupentixol-melitraeen can optimize the conventional therapeutic effect for postherpetic neuralgia.
作者
缪小菊
衣希
曾真
袁杰
文松
张德新
王捷
张桂友
曹嵩
Miao Xiaoju;Yi Xi;Zeng Zhen;Yuan Jie;Wen Song;Zhang Dexin;Wang Jie;Zhang Guiyou;Cao Song(Department of PainMedicine ,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China)
出处
《中华麻醉学杂志》
CAS
CSCD
北大核心
2018年第7期847-849,共3页
Chinese Journal of Anesthesiology